In September of 2022, GSK and Spero Therapeutics entered into an exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr. Tebipenem HBr is an oral carbapenem antibiotic aimed at treating complicated urinary tract infections including pyelonephritis. GSK will receive an exclusive license to develop and commercialise Tebipenem pivoxil and tebipenem pivoxil HBr in all territories […] The post BioSci Deal of the Month – Spero Therapeutics & GSK appeared first on Evaluate.
